articleThe Lancet OncologyJan 17, 2008Closed access

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Saarland University · Leipzig University · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,133
total citations
FWCI
46.13
Percentile
100%
References
19
Citations per year

Authors

26

Topics & keywords

Keywords
  • CHOP
  • Medicine
  • Rituximab
  • Vincristine
  • Internal medicine
  • Clinical endpoint
  • Lymphoma
  • Gastroenterology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding